tradingkey.logo
tradingkey.logo
Search

Beta Bionics Inc

BBNX
Add to Watchlist
16.760USD
+0.060+0.36%
Close 07/02, 13:00ETQuotes delayed by 15 min
746.85MMarket Cap
LossP/E TTM

Beta Bionics Inc

16.760
+0.060+0.36%
View Detailed Chart
TradingKey 图表
Intraday
1m
30m
1h
D
W
M
D

Today

+0.36%

5 Days

+5.34%

1 Month

+31.04%

6 Months

-42.70%

Year to Date

-45.00%

1 Year

+18.53%

Key Figures
16.710Open
17.060High
606.89KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
1.36%Turnover Ratio
16.700Prev. Close
16.175Low
7.57MTurnover
LossP/E Static
2.75P/B
0.00%Div Yield TTM
-20.68%ROA
32.71052wk High
1.01Volume Ratio
-54.76MNet Profit
44.56MShares
-1.3659EPS TTM
--Beta
-22.71%ROE
8.80052wk Low
5.30%Amplitude
59.50%Gross Margin
746.85MMarket Cap
7.39Reward/Risk
4.62%Risk Rate

TradingKey Stock Score of Beta Bionics Inc

Currency: USD Updated: 2026-07-02

Key Insights

Beta Bionics Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 40 out of 204 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 19.58.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Beta Bionics Inc's Score

Industry at a Glance

Industry Ranking
40 / 204
Overall Ranking
114 / 4565
Industry
Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Positive+

Beta Bionics Inc Highlights

StrengthsRisks
Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development and commercialization of various solutions to improve the health of insulin-requiring people with diabetes (PWD). The Company's product, the iLet Bionic Pancreas (iLet), is an insulin delivery device cleared by the United States Food and Drug Administration (FDA) to utilize adaptive closed-loop algorithms to autonomously determine every insulin dose without requiring a user to count carbohydrate intake. iLet is used for the treatment of Type 1 diabetes (T1D). The Company's solutions include iLet for Adults, iLet for Children, Bionic Circle App and iLet Simulator. The Company is in the early stages of developing an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing, commonly known in the diabetes industry as a patch pump. It is also in the early stages of developing a bihormonal configuration of the iLet.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 735.77% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 100.25M.
Fairly Valued
The company’s latest PE is -12.27, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 49.25M shares, decreasing 4.25% quarter-over-quarter.
Held by Steven Cohen
Star Investor Steven Cohen holds 2.18M shares of this stock.

Analyst Rating

Based on 12 analysts
Buy
Current Rating
19.583
Target Price
+15.20%
Upside Space

Beta Bionics Inc News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Beta Bionics Inc Info

Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development and commercialization of various solutions to improve the health of insulin-requiring people with diabetes (PWD). The Company's product, the iLet Bionic Pancreas (iLet), is an insulin delivery device cleared by the United States Food and Drug Administration (FDA) to utilize adaptive closed-loop algorithms to autonomously determine every insulin dose without requiring a user to count carbohydrate intake. iLet is used for the treatment of Type 1 diabetes (T1D). The Company's solutions include iLet for Adults, iLet for Children, Bionic Circle App and iLet Simulator. The Company is in the early stages of developing an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing, commonly known in the diabetes industry as a patch pump. It is also in the early stages of developing a bihormonal configuration of the iLet.
Ticker SymbolBBNX
CompanyBeta Bionics Inc
CEOSaint (Sean)
Websitehttps://www.betabionics.com

FAQs

What is the current price of Beta Bionics Inc (BBNX)?

The current price of Beta Bionics Inc (BBNX) is 16.76.

What is the symbol of Beta Bionics Inc?

The ticker symbol of Beta Bionics Inc is BBNX.

What is the 52-week high of Beta Bionics Inc?

The 52-week high of Beta Bionics Inc is 32.71.

What is the 52-week low of Beta Bionics Inc?

The 52-week low of Beta Bionics Inc is 8.80.

What is the market capitalization of Beta Bionics Inc?

The market capitalization of Beta Bionics Inc is 746.85M.

Is Beta Bionics Inc (BBNX) currently rated as Buy, Hold, or Sell?

According to analysts, Beta Bionics Inc (BBNX) has an overall rating of Buy, with a price target of 19.58.

What is the Earnings Per Share (EPS TTM) of Beta Bionics Inc (BBNX)?

The Earnings Per Share (EPS TTM) of Beta Bionics Inc (BBNX) is -1.81.